Abstract: Smac mimetics are being developed as a new class of anticancer therapies. Since the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TRAIL may be particularly attractive due to the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In the present study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, SM-164 in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study demonstrates that SM-164 is highly synergistic with TRAIL in vitro in both TRAILsensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer.
Abstract: Smac mimetics are being developed as a new class of anticancer therapies. Since the single-agent activity of Smac mimetics is very limited, rational combinations represent a viable strategy for their clinical development. The combination of Smac mimetics with TRAIL may be particularly attractive due to the low toxicity of TRAIL to normal cells and the synergistic antitumor activity observed for the combination. In the present study, we have investigated the combination synergy between TRAIL and a potent Smac mimetic, in vitro and in vivo and the underlying molecular mechanism of action for the synergy. Our study demonstrates that SM-164 is highly synergistic with TRAIL in vitro in both TRAILsensitive and TRAIL-resistant cancer cell lines of breast, prostate, and colon cancer.
Furthermore, the combination of SM-164 with TRAIL induces rapid tumor regression in vivo in a breast cancer xenograft model in which either agent is ineffective. Our data shows that XIAP and cIAP1, but not cIAP2, work in concert to attenuate the activity of TRAIL; SM-164 strongly enhances TRAIL activity by concurrently targeting XIAP and cIAP1. Moreover, while RIP1 plays a minimal role in TRAIL's activity as a single agent, it is required for the synergistic interaction between TRAIL and SM-164. Our present study provides a strong rationale to develop the combination of SM-164 and TRAIL as a new therapeutic strategy for the treatment of human cancer. Despite the strong synergy demonstrated between TRAIL and Smac mimetics, the precise underlying molecular mechanism of action for their synergy is not fully understood.
Because Smac mimetics have been designed based upon the interaction between XIAP and Smac, previous investigations have focused on XIAP as the primary cellular target for Smac mimetics when combined with TRAIL (36-39). However, our data clearly showed that while knock-out of XIAP or efficient knock-down of XIAP by siRNA can modestly sensitize cancer cells to apoptosis induction by TRAIL, the sensitization effect is far less than that achieved by Smac mimetics. In addition, although one would expect that the underlying molecular mechanism for the synergistic interaction between TRAIL and Smac mimetics may be very similar to that between TNFα and Smac mimetics, our data showed that TNFα fails to induce apoptosis in cancer cell lines of diverse tumor types which are very sensitive to TRAIL as a single agent, and Smac mimetics can dramatically sensitize TRAIL in both TRAIL-sensitive and -resistant cancer cell lines. Finally, despite the strong synergy between TRAIL and Smac mimetics in vitro, tumor regression has not been reported in vivo for the combination when both agents are ineffective.
We have previously reported the design and evaluation of SM-164 as a potent, bivalent Smac mimetic (28, 41). SM-164 binds to XIAP, cIAP1 and cIAP2 with K i values of 0.56 nM, 0.31 nM and 1.1 nM, respectively (28, 41). It potently antagonizes XIAP in cellfree functional assays and in cells, and induces rapid degradation of cIAP1 and cIAP2 in cancer cells at concentrations as low as 1-10 nM (28, 41). In the present study, we have employed SM-164 and evaluated its combination with recombinant TRAIL protein in a panel of 19 human breast, prostate and colon cancer cell lines in vitro and in a breast cancer xenograft model in vivo. Our study provides further insights into the molecular mechanism of action for the strong synergy between TRAIL and Smac mimetics and suggests that the combination of TRAIL with SM-164 or other Smac mimetics should be evaluated in the clinic as a new strategy for the treatment of human breast, prostate and colon cancer.
Materials and Methods
Reagents and Antibodies. SM-164 was synthesized as described previously (41) 12 min, and 4 °C) and cell pellet was stored in -80 °C or directly used for protein purification.
Cell pellet was resuspended in 40 ml lysis buffer (50mM Tris pH7.5, 200mM NaCl, 50uM
ZnAc, 1mM DTT) for sonication to release soluble proteins. TRAIL 114-281aa protein was purified by Ni-NTA affinity chromatography. The Ni-NTA resin was washed with 50 ml lysis buffer and recombinant protein was eluted with lysis buffer with 80 mM imidazole. The protein was further purified with size-exclusion chromatography using an Amersham Biosciences P-920 FPLC equipped with a Superdex 200 column (Amersham Biosciences).
The protein was eluted in a buffer containing 50mM Tris pH 7.5, 200 mM NaCl, 50 µM ZnAc, 10 mM DTT and 10% glycerol and then stored at -80 °C. The activity of this recombinant TRAIL was comparable with a commercial TRAIL (R&D Systems) and was found to be identical. Flag-tagged TRAIL was purchased from Alexis Biochemicals (San Diego, CA).
The following primary antibodies were used in this study: and 1 protease inhibitor cocktail tablet per 10 mL on ice for 20 min, and lysates were then cleared by centrifugation before determination of protein concentration using the Bio-Rad protein assay kit according to the manufacturer's instructions. Proteins were electrophoresed onto 4-20% SDS-PAGE gels (Invitrogen, Carlsbad, CA) and transferred onto polyvinylidene difluoride membranes. Following blocking in 5% milk, membranes were incubated with a specific primary antibody, washed, and incubated with horseradish peroxidase-linked secondary antibody (GE Healthcare, Piscataway, NJ). Signals were visualized with chemiluminescent horseradish peroxidase antibody detection reagent (Denville Scientific, Metuchen, NJ). Where indicated, the blots were stripped and reprobed with a different antibody.
Co-immunoprecipitation. TRAIL-receptor complex was immunoprecipitated with Flagtagged TRAIL, based on the reported protocol (28). A total of 5x10 7 cells of each sample in 10 ml culture medium were treated with the mixture of 100 ng/ml of Flag-tagged TRAIL and anti-Flag M2 IgG (3 µg/ml for each sample) at 37°C and then lysed for 30 min on ice with the lysis buffer. The soluble fraction was pulled down with sepharose 4B beads overnight at 4°C and subjected to Western blot analysis. For the analysis of the TRAIL-dependent secondary signaling complex, after immunoprecipitation of the DISC, DISC-depleted cell lysates were subjected to a second round of immunoprecipitation using anti-RIP1, followed by western blotting analysis of co-immunoprecipitated procaspase-8 and cIAP1.
RNA interference. RNA interference was performed as described previously (23).
Briefly, siRNA was used to knock down XIAP, cIAP1, cIAP2, and caspase-8, -9, and -3 (Dhamarcon Research, Inc.). Non-targeting control siRNA was purchased from Ambion. effect in sensitizing TRAIL in these cell lines, whereas knockdown of cIAP2 alone has little or no effect compared to the control siRNA ( Taken together, our data show that cIAP2 has a minimal role in blocking TRAIL activity in these cancer cell lines.
To complement these siRNA experiments, we employed HCT116 XIAP +/+ and XIAP -/-isogenic cell lines (46) . Consistent with the original study (46) , knockout of XIAP makes the HCT116 cells more sensitive than its wild-type counterpart to TRAIL-induced cell viability inhibition, but SM-164 is much more effective than the XIAP gene knockout in sensitizing TRAIL in HCT116 XIAP -/-cells ( knockdown of cIAP2 has a minimal effect (Fig. 3D) . Interestingly, although knockdown of cIAP1 again greatly increases the levels of cIAP2 protein, simultaneous knockdown of cIAP1 and cIAP2 in the HCT116 XIAP -/-cells does not further sensitize the cells to TRAIL as compared to knock-down of cIAP1 alone (Fig. 3D) . In addition, when cIAP1 is knocked down in the HCT116 XIAP -/-cells, addition of SM-164 fails to further sensitize the cells to TRAIL (Fig. 3D) . 
and RIP1 to the complex (Fig. 4A and SI Fig. S10 ). While similar levels of DR4 and DR5 are found in the TRAIL-DISC complex with or without treatment of SM-164, the recruitments of procaspase-8 to the TRAIL-DISC are greatly enhanced at very early time-points with SM-164 ( Fig. 4 and SI Fig. S10 ).
To test directly whether SM-164 promotes the TRAIL-DISC formation through induction of cIAP1 degradation, the TRAIL-receptor complex was analyzed in 2LMP cells transfected with siRNA against cIAP1, cIAP2 or XIAP. Knockdown of cIAP1 strongly enhances procaspase-8 recruitment following TRAIL treatment (Fig. 4B ) as compared with non-targeting siRNA, whereas recruitment of procaspase-8 was essentially unchanged in cells transfected with XIAP siRNA and non-targeting siRNA. In contrast to cIAP1, knockdown of cIAP2 does not enhance, and may in fact attenuate, recruitment of procaspase-8 (Fig. 4B ).
These data indicate that cIAP1 degradation by SM-164 greatly promotes TRAIL-DISC formation.
Ablation of cIAP1 facilitates the interaction between RIP1 and caspase-8.
Ablation of cIAP1 by Smac mimetics was shown to greatly enhance recruitment of RIP1 to the TNFα−receptor complex (25, 26), which plays a major role in activation of caspase-8 and apoptosis induction by Smac mimetics as a single agent. We therefore examined the recruitment of RIP1 to the TRAIL-receptor complex and the role of RIP1 in apoptosis induction by TRAIL alone and in combination with SM-164. 
In contrast to the marked enhancement of RIP1 recruitment to TNFα−receptor complex by Smac mimetics (25, 26), ablation of cIAP1 by SM-164 or siRNA has little or no effect on the recruitment of RIP1 to TRAIL-receptor complex at all the time-points examined (Fig. 4A-B and SI Fig. S10 ).
We next investigated the interaction between RIP1 and caspase-8 in the cytoplasm.
Upon TRAIL treatment, RIP1 forms a complex with caspase-8 within 10 min upon TRAIL treatment, which is markedly increased at the 30 min time-point (Fig. 4A lower panel) and TRAIL-stimulation also leads to an interaction of RIP1 with cIAP1 within 5 min. At each time point examined, degradation of cIAP1 by SM-164 markedly enhances the interaction between RIP1 and caspase-8 ( Fig. 4A lower panel) . To further investigate the role of XIAP, cIAP1, and cIAP2 on the interaction of RIP1 with caspase-8, RIP1-immunoprecipitation was performed using the TRAIL-receptor complex-depleted lysates from cells transfected with siRNA against each IAP (Fig. 4B) . While knockdown of cIAP1 markedly enhances the interaction between RIP1 and caspase-8, knockdown of XIAP has a minimal effect and knockdown of cIAP2 appears even to inhibit the interaction (Fig. 4B) . Western blotting showed the absence of DR4 and DR5 in the RIP1-immunoprecipitation, indicating that the interaction of RIP1 with cIAP1 and caspase-8 occurs primarily in the cytoplasm (Fig. 4A lower panel). Collectively, these data indicate that cIAP1 markedly inhibits the interaction of RIP1 and caspase-8 upon TRAIL-stimulation and that degradation of cIAP1 greatly enhances this interaction in the cytoplasm and promotes the activation of caspase-8. Western blot (Fig. 5A-C) . Efficient RIP1 knockdown has only a modest effect on cell death induction, cell viability inhibition, activation of caspases and cleavage of PARP by TRAIL as a single agent in 2LMP cells. In contrast, RIP1 knockdown effectively blocks the robust sensitization to TRAIL by SM-164 in 2LMP cells (Fig. 5A-C) . Similarly, efficient RIP1 knockdown in MDA-MB-436 and MDA-MB-468 cell lines has little or no effect in cell viability inhibitory activity by TRAIL but effectively blocks the sensitization by SM-164 in both cell lines (SI Fig. S11-12 ). In the TRAIL-resistant MDA-MB-453 cancer cell line, efficient RIP1 knockdown has no effect on the activity of TRAIL and SM-164 as a single agent, but it blocks the robust cleavage of PARP and processing of caspase-8 and -3 and cell viability inhibition by the combination (SI Fig. S13A-B) . To complement the siRNA experiments, we next employed the Jurkat cell line and its RIP1 knock-out counterpart to further investigate the role of RIP1 (49) . While SM-164 clearly sensitizes TRAIL in inhibition of cell viability in the Jurkat parental cell line, SM-164 is completely ineffective in enhancing the activity of TRAIL in the Jurkat RIP1 knock-out cell line (Fig. 5D ).
These data show that while RIP1 plays a minimal role in the activity of TRAIL as a single agent, it is required for the synergistic interaction between SM-164 and TRAIL.
SM-164 enhances apoptosis induction by TRAIL in xenograft tumor tissues and their combination achieves tumor regression
To further evaluate the therapeutic potential of SM-164 in combination with TRAIL, we tested the in vivo activity for TRAIL and SM-164 as single agents and their combination using the 2LMP xenograft model.
A single dose of SM-164 at 5 mg/kg i.v. is highly effective in induction of cIAP1 degradation (Fig. 6A) , but fails to induce caspase-3 activation, PARP cleavage or apoptosis over a 6-24 h time period in tumor tissues (Fig. 6A-B) . Although TRAIL is very effective as a single agent in cell viability inhibition in vitro in the 2LMP cell line, a single dose of TRAIL at 10 mg/kg induces only modest caspase-3 activation, PARP cleavage and minimal apoptosis in tumor tissues (Fig. 6A-B) . In contrast, their combination induces robust caspase-3 activation, PARP cleavage and strong apoptosis in tumor tissues (Fig. 6A-B) ; 50% of tumor cells are in fact TUNEL positive in tumor tissues at the 6 h time-point (Fig. 6B, right SI Fig. S14 ). H&E staining further showed that the combination causes extensive damage to tumor tissues (Fig. 6C) . In comparison, SM-164, TRAIL alone and their combination have no effect on all normal mouse tissues examined, including highly proliferative tissues such as spleen, small intestine and bone marrow (SI Fig. S15 ).
We next examined the combination efficacy, as well as potential toxicity with systemic administration of these two agents against established 2LMP tumors (Fig. 6D) . SM-164 (5 mg/kg, i.v. daily, five days/week and TRAIL (10 mg/kg i.p. daily, five days/week) were administered alone or in combination for two weeks. Although neither SM-164 nor TRAIL as single agents results in any signs of toxicity in mice, they fail to achieve any significant antitumor activity. In contrast, their combination induces tumor regression. At the end of the treatment, the combination reduces the mean tumor volume by 80% and the tumors in the combination treatment group continue to shrink after treatment ended and are undetectable on day 33 in 6 out of 8 cases. This strong antitumor activity by SM-164 is persistent and three of the 8 tumors remain completely regressed three months after the treatment concluded. In comparison, the mean tumor volume in the control and the treatment groups with TRAIL alone or SM-164 alone are over 1000 mm 3 on day 43 (Fig. 6D, left 
panel).
The combination treatment causes no gross abnormalities or other signs of toxicity.
Mice treated with the combination experience a slight but statistically insignificant body weight loss at the end of 2 weeks of treatment and all regain their weight by day 33 (Fig. 6D, 
right panel).
on Our data supported that similar to TNFα, TRAIL induces apoptosis through both Rip1-dependent and -independent pathways (47) . As a single agent, TRAIL induces apoptosis in a RIP1-independent manner. The synergy between TRAIL and Smac mimetics, however, relies on the interaction of procaspase-8 with RIP1 and is RIP1-dependent.
Knockdown of RIP1 abrogates or dramatically attenuates cell viability inhibition by the combination (Fig.4B-C, Fig.5A-D) . This RAP1-depedndent event takes place once cIAP1 is removed by a Smac mimetic or siRNA (Fig.4A, C, Fig.5A-D) . The interaction of procaspase-8 and RIP1 is detected in the cytoplasm (Fig.4B-C) , demonstrating that RIP1-dependent caspase-8 activation primarily takes place in cytoplasm. However, removal of cIAP1 also markedly increases the procaspase-8 recruitment to TRAIL-receptor complex (Fig.4A) .
Although SM-164 potently antagonizes XIAP and induces efficient down-regulation of cIAP1 in all the cancer cell lines we have evaluated in the present study, SM-164 enhances the anticancer activity of TRAIL in the majority but not all of cancer cell lines examined.
These data show that while XIAP and cIAP1effectively inhibit the activity of TRAIL, they In summary, our present study furthers our understanding on the underlying molecular mechanism of the strong synergy between Smac mimetics and TRAIL and provides strong support that the combination of Smac mimetics and TRAIL should be evaluated in the clinic as a new cancer therapeutic strategy for the treatment of a variety of human cancers. 
